

Resistant *Pseudomonas aeruginosa* Infections - Pipeline Review, H2 2020

<https://marketpublishers.com/r/R1E54569A56EN.html>

Date: September 2020

Pages: 57

Price: US\$ 2,000.00 (Single User License)

ID: R1E54569A56EN

Abstracts

Resistant *Pseudomonas aeruginosa* Infections - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Resistant *Pseudomonas aeruginosa* Infections - Pipeline Review, H2 2020, provides an overview of the Resistant *Pseudomonas aeruginosa* Infections (Infectious Disease) pipeline landscape.

Pseudomonas aeruginosa has become an important cause of infection, especially in patients with compromised host defense mechanisms. It has an ability to rapidly develop resistance to multiple classes of antibiotics. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include pneumonia, fever, fatigue, itchy rash, bleeding ulcers and headache. Risk factors include age and weakened immune system.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Resistant *Pseudomonas aeruginosa* Infections - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Resistant *Pseudomonas aeruginosa* Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Resistant *Pseudomonas aeruginosa* Infections (Infectious Disease) pipeline guide

also reviews of key players involved in therapeutic development for Resistant *Pseudomonas aeruginosa* Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 1, 1, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 3 molecules, respectively.

Resistant *Pseudomonas aeruginosa* Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Resistant *Pseudomonas aeruginosa* Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Resistant *Pseudomonas aeruginosa* Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Resistant *Pseudomonas*

aeruginosa Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Resistant *Pseudomonas aeruginosa* Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Resistant *Pseudomonas aeruginosa* Infections (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Resistant *Pseudomonas aeruginosa* Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Resistant *Pseudomonas aeruginosa* Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Resistant *Pseudomonas aeruginosa* Infections - Overview

Resistant *Pseudomonas aeruginosa* Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Resistant *Pseudomonas aeruginosa* Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Resistant *Pseudomonas aeruginosa* Infections - Companies Involved in Therapeutics Development

AMR Centre Ltd

Armata Pharmaceuticals Inc

Biolytics Pharma

Boston Pharmaceuticals Inc

Inhibrx Inc

Linnaeus Bioscience Inc

Shionogi & Co Ltd

VenatoRx Pharmaceuticals Inc

Resistant *Pseudomonas aeruginosa* Infections - Drug Profiles

(cefepime + taniborbactam hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(ciprofloxacin + colistimethate sodium) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APPA-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Multi-Drug Resistant *Pseudomonas aeruginosa* Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for *Pseudomonas Aeruginosa* Infection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Resistant *Pseudomonas aeruginosa* Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BOS-181 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cefiderocol sulfate tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

COT-143 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INBRX-111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEG-2S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for *Pseudomonas aeruginosa* Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Resistant *Pseudomonas aeruginosa* Infections - Dormant Projects

Resistant *Pseudomonas aeruginosa* Infections - Product Development Milestones

Featured News & Press Releases

Apr 18, 2018: Shionogi to Present New Data on COT-143 at 2018 European Congress of Clinical Microbiology and Infectious Diseases

Oct 31, 2017: Inhibrx Wins CARB-X Award Of Up To \$6.0M To Accelerate Development Of Its Novel Antibody, INBRX-111, To Treat Pseudomonas Infections

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Resistant *Pseudomonas aeruginosa* Infections, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Resistant *Pseudomonas aeruginosa* Infections - Pipeline by AMR Centre Ltd, H2 2020

Resistant *Pseudomonas aeruginosa* Infections - Pipeline by Armata Pharmaceuticals Inc, H2 2020

Resistant *Pseudomonas aeruginosa* Infections - Pipeline by Biolytics Pharma, H2 2020

Resistant *Pseudomonas aeruginosa* Infections - Pipeline by Boston Pharmaceuticals Inc, H2 2020

Resistant *Pseudomonas aeruginosa* Infections - Pipeline by Inhibrx Inc, H2 2020

Resistant *Pseudomonas aeruginosa* Infections - Pipeline by Linnaeus Bioscience Inc, H2 2020

Resistant *Pseudomonas aeruginosa* Infections - Pipeline by Shionogi & Co Ltd, H2 2020

Resistant *Pseudomonas aeruginosa* Infections - Pipeline by VenatoRx Pharmaceuticals Inc, H2 2020

Resistant *Pseudomonas aeruginosa* Infections - Dormant Projects, H2 2020

Resistant *Pseudomonas aeruginosa* Infections - Dormant Projects, H2 2020 (Contd..1), H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Resistant *Pseudomonas aeruginosa* Infections, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Targets, H2 2020

Number of Products by Stage and Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

AMR Centre Ltd

Armata Pharmaceuticals Inc

Biolytics Pharma

Boston Pharmaceuticals Inc

Inhibrx Inc

Linnaeus Bioscience Inc

Shionogi & Co Ltd

VenatoRx Pharmaceuticals Inc

I would like to order

Product name: Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/R1E54569A56EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R1E54569A56EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970